S Protein Interaction Inhibitors for ACE2-Independent COVID-19 Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for COVID-19 are inadequate in addressing the hyperactive immunopathology and excessive inflammation caused by SARS-CoV-2 infection, particularly in myeloid cells, due to the unclear role of host molecules other than ACE2 in viral entry and the inefficacy of blocking the S protein RBD-ACE2 interaction.
Innovation Solution
Development of inhibitors, such as antibodies and antibody fragments, targeting the binding of SARS-CoV-2 S protein to additional interacting partners like ACE2, C-type lectins (DC-SIGN, L-SIGN, LSECtin, ASGR1, CLEC10A, and TTYH2), which can block viral entry into host cells and modulate immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic approaches block the S protein RBD-ACE2 interaction, then viral entry through ACE2 is inhibited, but the therapy is insufficient because it does not address other entry factors and immune cell infection
Solution Approach 1:
The patent develops inhibitors that can block multiple SARS-CoV-2 entry mechanisms simultaneously - both ACE2-dependent and ACE2-independent pathways. The inhibitors target multiple interacting partners including ACE2, C-type lectins, and other host molecules, making the therapy universally effective against diverse viral entry mechanisms rather than being limited to a single pathway.
Solution Approach 2:
The patent segments the viral entry process into multiple independent pathways and targets each with specific inhibitors. By identifying and blocking separate entry factors (ACE2, C-type lectins, and other host molecules), the therapy divides the complex entry mechanism into manageable segments that can be addressed individually and comprehensively.
2Quantity of substance
If pharmacological interventions aim to reduce SARS-CoV-2 replication, then viral load is decreased, but clinical symptoms in severe cases remain unchanged due to hyperactive immunopathology
Solution Approach 1:
The patent applies preliminary action by blocking viral entry and infection of immune cells before the hyperactive immunopathology can develop. By preventing SARS-CoV-2 from entering and infecting myeloid cells in advance, the therapy stops the cascade of proinflammatory cytokine production at its source, rather than attempting to treat the immunopathology after it has fully developed.
3Reliability
If ACE2 is the major cellular receptor for SARS-CoV-2 entry, then viral infection is blocked at the primary entry point, but the therapy fails to address ACE2-independent entry through other host molecules
Solution Approach 1:
The patent develops inhibitors that can block multiple SARS-CoV-2 entry mechanisms simultaneously - both ACE2-dependent and ACE2-independent pathways. The inhibitors target multiple interacting partners including ACE2, C-type lectins, and other host molecules, making the therapy universally effective against diverse viral entry mechanisms rather than being limited to a single pathway.
Data Source
AI summary
The invention provides compositions and methods for inhibiting the interaction of the SARS-CoV-2 S protein and one or more SARS-CoV-2 S protein interacting protein, and methods of use thereof.